

# PriorityActions

IMPORTANT UPDATES FOR OUR PROVIDER NETWORK

Dec. 18, 2025 | Issue #3.25

## December 2025 billing policy updates

[Billing and payment news](#)

We publish billing policies to offer transparency and help providers bill claims more accurately to reduce delays in processing claims, as well as avoid rebilling and additional requests for information. We add new and update several existing policies each month. | [Read More](#)

---

## Code 0523T FRR not separately payable

[Billing and payment news](#)

We're correcting an issue with CPT code 0523T which was requiring a prior authorization in error. This code is not separately payable from the primary procedure for all products. | [Read More](#)

---

## New process for submitting Part D immunizations for PriorityMedicare members

[Billing and payment news](#)

Effective Jan. 1, 2026, providers must bill Part D immunizations for PriorityMedicare Dual Premier (HIDE-SNP) members through TransactRx when vaccines are administered in a physician's office. Claims submitted directly to us will deny as provider liability, and providers may not bill members for any vaccine costs or administration fees. The TransactRx process is available for all PriorityMedicare members. | [Read More](#)

---

# We're updating our processes for inpatient acute authorizations, effective Jan. 1, 2026

[Authorizations news](#)

Effective Jan. 1, 2026, we're updating the peer-to-peer and appeal processes for inpatient acute authorization requests for Medicare and Medicaid, to be in compliance with CMS regulations and state recommendations for HIDE-SNP implementation. | [Read More](#)

---

## GLP-1 weight-loss drug coverage changes coming for Medicaid members

[Pharmacy news](#)

Effective Jan. 1, 2026, coverage and criteria of GLP-1 weight-loss drugs Saxenda, Wegovy and Zepbound will become more restricted for Medicaid members. | [Read More](#)

---

## Formulary updates: Tysabri and Revlimid coverage changes coming

[Pharmacy news](#)

### Tysabri®

Effective Mar. 1, 2026, Tysabri will be removed from medical drug coverage, while its generic, tykuro, will be added to medical drug coverage for our commercial group and individual members.

### Revlimid®

Effective Feb. 1, 2026, Revlimid will be removed from pharmacy benefit coverage for our commercial group and individual members and from our SaveOnSP drug list for members who participate in this program. |

[Read More](#)

---

## Final reminder: You must complete our 15-minute, CMS-required D-SNP Model of Care training by Dec. 31

[Requirements and responsibilities news](#)

Providers play an integral role in the care teams that support our dual-eligible special needs (D-SNP) members. That's why the Centers for Medicare and Medicaid Services (CMS) requires us to make sure providers who are contracted with us to see PriorityMedicare patients

are trained on our Model of Care (MOC) every year. If you have not yet done so, please complete your training as soon as possible by following our step-by-step instructions. | [Read More](#)

## Reminder: Physician signatures required on Medicaid Children's Special Health Care Services documentation

[Clinical resources news](#)

Priority Health Medicaid members under the age of 26 may be eligible for coverage through the Michigan Children's Special Health Care Services (CSHCS) program. To support eligibility determinations, MDHHS requires timely documentation of the member's diagnosis and treatment plan. If Priority Health requests this documentation from you on behalf of a Medicaid member, please be sure it is signed by a licensed physician (MD or DO) when you submit it. | [Read More](#)

You're receiving this email because you're part of an Accountable Care Network (ACN) or Provider Organization (PO) with us. Please share relevant information with your provider groups and practices.

Questions?

Connect with your Provider Network Management specialist, [Jacquie Andrews](#).

Access an archive of our PriorityActions for providers emails [here](#).



©2025 Priority Health  
1231 E. Beltline Ave. NE  
Grand Rapids, MI 49525-7024

This email is confidential and intended for the recipient specified in this message only. It is strictly forbidden to share any part of this message without a written consent of the sender. If you received this email in error, please reply informing us of the error and then delete it from your inbox.

[Nondiscrimination notice](#) | [Language assistance](#)  
[View in browser](#) | [Unsubscribe](#)